Zymeworks Inc.

Catalyst AI-extracted

zanidatamab

HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma

Resolved

7days ago

Catalyst readout · ~ Jun 30, 2026 estimated

What's at stake A key catalyst for zanidatamab (HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma) is expected ~ Jun 30, 2026.

Primary source · SEC 8-K verified 15h ago

“The second interim overall survival analysis for the HERIZON-GEA-01 trial is expected in mid-2026”